174 related articles for article (PubMed ID: 38643252)
1. One-year visual and anatomical outcomes of intravitreal faricimab injection for neovascular age-related macular degeneration after prior brolucizumab treatment.
Takahashi H; Inoda S; Takahashi H; Takahashi R; Hashimoto Y; Yoshida H; Kawashima H; Yanagi Y
Sci Rep; 2024 Apr; 14(1):9087. PubMed ID: 38643252
[TBL] [Abstract][Full Text] [Related]
2. Comparison of functional and morphologic changes between brolucizumab and faricimab in neovascular age-related macular degeneration.
Maruyama-Inoue M; Yanagi Y; Inoue T; Kadonosono K
Graefes Arch Clin Exp Ophthalmol; 2024 Feb; 262(2):589-599. PubMed ID: 37750953
[TBL] [Abstract][Full Text] [Related]
3. One-year results of treat-and-extend regimen with intravitreal faricimab for treatment-naïve neovascular age-related macular degeneration.
Matsumoto H; Hoshino J; Nakamura K; Akiyama H
Jpn J Ophthalmol; 2024 Mar; 68(2):83-90. PubMed ID: 38244172
[TBL] [Abstract][Full Text] [Related]
4. Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration.
Kataoka K; Itagaki K; Hashiya N; Wakugawa S; Tanaka K; Nakayama M; Yamamoto A; Mukai R; Honjyo J; Maruko I; Kawai M; Miyara Y; Terao N; Wakatsuki Y; Onoe H; Mori R; Koizumi H; Sekiryu T; Iida T; Okada AA;
Graefes Arch Clin Exp Ophthalmol; 2024 Jan; 262(1):43-51. PubMed ID: 37668741
[TBL] [Abstract][Full Text] [Related]
5. One-year results of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization.
Matsumoto H; Hoshino J; Mukai R; Nakamura K; Akiyama H
Sci Rep; 2022 May; 12(1):8195. PubMed ID: 35581196
[TBL] [Abstract][Full Text] [Related]
6. Visual and Anatomical Outcomes After Initial Intravitreal Faricimab Injection for Neovascular Age-Related Macular Degeneration in Patients with Prior Treatment History.
Inoda S; Takahashi H; Takahashi R; Hashimoto Y; Yoshida H; Takahashi H; Takayama T; Kawashima H; Yanagi Y
Ophthalmol Ther; 2023 Oct; 12(5):2703-2712. PubMed ID: 37531030
[TBL] [Abstract][Full Text] [Related]
7. Short-term outcomes of switching to brolucizumab in japanese patients with neovascular age-related macular degeneration.
Kitajima Y; Maruyama-Inoue M; Ikeda S; Ito A; Inoue T; Yanagi Y; Kadonosono K
Jpn J Ophthalmol; 2022 Nov; 66(6):511-517. PubMed ID: 36149566
[TBL] [Abstract][Full Text] [Related]
8. Real-world experience with brolucizumab in neovascular age-related macular degeneration over 2 years: the REBA extension study.
Bilgic A; Kodjikian L; de Ribot FM; Spitzer MS; Vasavada V; Gonzalez-Cortes JH; Sudhalkar A; Chakraborty S; Mathis T
Graefes Arch Clin Exp Ophthalmol; 2024 Apr; 262(4):1161-1167. PubMed ID: 38063874
[TBL] [Abstract][Full Text] [Related]
9. Switching from aflibercept to brolucizumab for the treatment of refractory neovascular age-related macular degeneration.
Ota H; Takeuchi J; Nakano Y; Horiguchi E; Taki Y; Ito Y; Terasaki H; Nishiguchi KM; Kataoka K
Jpn J Ophthalmol; 2022 May; 66(3):278-284. PubMed ID: 35233693
[TBL] [Abstract][Full Text] [Related]
10. Investigation of satisfaction with short-term outcomes after switching to faricimab to treat neovascular age-related macular degeneration.
Hikichi T
Jpn J Ophthalmol; 2023 Nov; 67(6):652-656. PubMed ID: 37861941
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studies.
Baumal CR; Sørensen TL; Karcher H; Freitas RL; Becher A; Balez S; Clemens A; Singer M; Kodjikian L
Acta Ophthalmol; 2023 Mar; 101(2):123-139. PubMed ID: 36117281
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal faricimab for neovascular age-related macular degeneration previously treated with traditional anti-VEGF compounds: a real-world prospective study.
Grimaldi G; Cancian G; Rizzato A; Casanova A; Perruchoud-Ader K; Clerici M; Consigli A; Menghini M
Graefes Arch Clin Exp Ophthalmol; 2024 Apr; 262(4):1151-1159. PubMed ID: 38047930
[TBL] [Abstract][Full Text] [Related]
13. Real-Life Experience and Predictors of Visual Outcomes with Intravitreal Brolucizumab Switch for Treatment of Neovascular Age-Related Macular Degeneration.
Cavalleri M; Tombolini B; Sacconi R; Gatta G; Valeri R; Bandello F; Querques G
Ophthalmologica; 2023; 246(2):158-168. PubMed ID: 37040734
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review and meta-analysis.
Yen WT; Wu CS; Yang CH; Chen YH; Lee CH; Hsu CR
Sci Rep; 2024 Jan; 14(1):2485. PubMed ID: 38291069
[TBL] [Abstract][Full Text] [Related]
15. Short-Term Outcomes of Faricimab in Patients with Neovascular Age-Related Macular Degeneration on Prior Anti-VEGF Therapy.
Szigiato A; Mohan N; Talcott KE; Mammo DA; Babiuch AS; Kaiser PK; Ehlers JP; Rachitskaya A; Yuan A; Srivastava SK; Sharma S
Ophthalmol Retina; 2024 Jan; 8(1):10-17. PubMed ID: 37673396
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal Aflibercept versus Brolucizumab for Treatment-Naive Neovascular Age-Related Macular Degeneration with Type 1 Macular Neovascularization: Comparison of Short-Term Outcomes.
Hoshino J; Matsumoto H; Mukai R; Nakamura K; Akiyama H
Ophthalmologica; 2022; 245(5):413-420. PubMed ID: 35834995
[TBL] [Abstract][Full Text] [Related]
17. Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degeneration: a short-term multicenter study.
Tamashiro T; Tanaka K; Itagaki K; Nakayama M; Maruko I; Wakugawa S; Terao N; Onoe H; Wakatsuki Y; Ogasawara M; Sugano Y; Yamamoto A; Kataoka K; Izumi T; Kawai M; Mori R; Sekiryu T; Okada AA; Iida T; Koizumi H;
Graefes Arch Clin Exp Ophthalmol; 2022 Jun; 260(6):1857-1865. PubMed ID: 35034215
[TBL] [Abstract][Full Text] [Related]
18. Brolucizumab for recalcitrant macular neovascularization in age-related macular degeneration with pigment epithelial detachment.
Chronopoulos A; Huynh E; Ashurov A; Schutz JS; Jonas JB; Hattenbach LO
Eur J Ophthalmol; 2024 Mar; 34(2):487-496. PubMed ID: 37461836
[TBL] [Abstract][Full Text] [Related]
19. Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization.
Matsumoto H; Hoshino J; Nakamura K; Akiyama H
Sci Rep; 2023 Feb; 13(1):3249. PubMed ID: 36828853
[TBL] [Abstract][Full Text] [Related]
20. One-year outcome of brolucizumab for neovascular age-related macular degeneration in Japanese patients.
Inoda S; Takahashi H; Takahashi R; Hashimoto Y; Yoshida H; Tsukii R; Takahashi H; Kawashima H; Yanagi Y
Sci Rep; 2024 Jan; 14(1):2451. PubMed ID: 38291120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
